SRR8613717
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- IL6_JAK_STAT3_SIGNALING+0.430
- TNFA_SIGNALING_VIA_NFKB+0.430
- ALLOGRAFT_REJECTION+0.420
- INFLAMMATORY_RESPONSE+0.410
- INTERFERON_GAMMA_RESPONSE+0.400
- COMPLEMENT+0.380
- UV_RESPONSE_DN+0.340
- COAGULATION+0.300
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.430
- MYC_TARGETS_V2-0.380
- BILE_ACID_METABOLISM-0.340
- DNA_REPAIR-0.330
- ADIPOGENESIS-0.300
- PEROXISOME-0.290
- FATTY_ACID_METABOLISM-0.190
- NOTCH_SIGNALING-0.160
- GLYCOLYSIS-0.130
- MTORC1_SIGNALING-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ffe7358d-31b2-4d92-93eb-0a88abaf2dca | — | — | 0.898 |
| 2 | TCGA-GV-A3QG-01A-11R-A220-07 | — | — | 0.892 |
| 3 | TCGA-DK-A3IU-01A-11R-A20F-07 | — | — | 0.891 |
| 4 | SRR29022840 | — | A | 0.881 |
| 5 | TCGA-FD-A3B8-01A-31R-A20F-07 | — | — | 0.873 |
| 6 | cadbc884-10b6-41e4-8aee-dc11a1453b8c | — | — | 0.869 |
| 7 | aad90266-d469-4986-b260-d0df4c2f48e7 | — | — | 0.867 |
| 8 | c7a22797-676e-4f10-a51d-e3ee91a29a21 | — | — | 0.864 |
| 9 | SRR6013514 | — | cohortMD2 | 0.862 |
| 10 | SRR10900557 | — | — | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.430 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.250 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |